fig3
![Targeting EZH2 for the treatment of soft tissue sarcomas](https://image.oaes.cc/7fffb25c-40ad-47b6-9465-b25a8e2f863b/3955.fig.3.jpg)
Figure 3. Soft tissue sarcomas (STS) are thought to be derived from lineage committed mesenchymal stem cells. Aberrant EZH2 expression and/or activity is believed to prevent normal terminal differentiation, leading to continued proliferation and poorly differentiated phenotypes in STS.